A Potential Drug Target or Biomarker: A Journey for TVP23C family in the Context of sequence similarity 18

Target Name: TVP23C

NCBI ID: G201158

TVP23C

A Potential Drug Target or Biomarker: A Journey for TVP23C family in the Context of sequence similarity 18

The TVP23C family, member B2, has been identified as a potential drug target or biomarker due to its unique sequence similarity, which has led to its increased interest in the pharmaceutical industry. This article will provide an overview of the TVP23C family, its potential drug targets, and its potential as a biomarker for various diseases.

The TVP23C Family

The TVP23C family is a group of non-coding RNAs that possess a characteristic sequence similarity of 18 between their 5'- and 3'-ends. This sequence similarity is unique among non-coding RNAs and has led to the family's increased interest in drug targets and biomarkers.

Potential Drug Target

The TVP23C family member B2 has been shown to have a unique binding site on a protein called EGFR, which is a transmembrane receptor that is involved in various signaling pathways, including cell growth, angiogenesis, and cancer progression. The binding of B2 to EGFR has been shown to enhance the activity of EGFR, leading to increased cell proliferation and survival.

Furthermore, B2 has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Therefore, the TVP23C family member B2 is a promising drug target for the treatment of various diseases.

Potential Biomarker

The TVP23C family member B2 has also been shown to serve as a potential biomarker for various diseases. The increased expression of B2 has been observed in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Furthermore, the levels of B2 have been shown to be decreased in diseases, which could indicate its potential as a biomarker. The potential use of B2 as a biomarker in disease diagnosis and monitoring makes it an attractive candidate for future research.

Understanding the Structure-Activity Interface

The unique sequence similarity of the TVP23C family member B2 has led to a better understanding of its structure-activity interface (SAI). The SAI is the interface between the sequence of interest (in this case, the 18-mer sequence of B2) and the target protein, leading to increased interaction between the sequence and the protein.

The SAI of B2 has been shown to be involved in various signaling pathways, including cell growth, angiogenesis, and cancer progression. This suggests that B2 plays a critical role in these processes and can be a valuable drug target or biomarker.

Conclusion

In conclusion, the TVP23C family member B2 has a unique sequence similarity of 18 and has been shown to have potential as a drug target or biomarker. The increased expression of B2 and its role in various diseases make it an attractive candidate for future research. Further studies are needed to fully understand the SAI of B2 and its potential as a drug target or biomarker.

Protein Name: Trans-golgi Network Vesicle Protein 23 Homolog C

The "TVP23C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TVP23C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets